Michael J Mckenna

US Patent:

20120309030, Dec 6, 2012

Filed:

Oct 28, 2010

Appl. No.:

13/504478

Inventors:

Michael P. McKenna - Branford CT, US
Michael Rowe - Oakland CA, US
Robert W. Gerwien - Newington CT, US

Assignee:

TETHYS BIOSCIENCE, INC. - Emeryville CA

International Classification:

G06F 19/24
G01N 21/78
G01N 21/76
G01N 21/75

US Classification:

435 724, 435 14, 435 792, 702 19

Abstract:

A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.

US Patent:

20120328594, Dec 27, 2012

Filed:

Oct 28, 2010

Appl. No.:

13/504720

Inventors:

Michael P. McKenna - Branford CT, US
Steve M. Watkins - Sacramento CA, US

Assignee:

TETHYS BIOSCIENCE, INC. - Emeryville

International Classification:

C40B 30/04
A61K 38/44
G06Q 50/22
G06F 19/00
G06G 7/60
C40B 40/10
A61P 3/10

US Classification:

424 944, 506 9, 506 18, 702 19, 703 11, 705 2

Abstract:

The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.

US Patent:

D3938760, Apr 28, 1998

Filed:

Jan 3, 1997

Appl. No.:

D/064538

Inventors:

Curtis Gray - Stratford CT
Michael J. McKenna - Shelton CT
Christine Weigand - Milford CT

Assignee:

BIC Corporation - Milford CT

International Classification:

1906

US Classification:

D19 50

US Patent:

59845562, Nov 16, 1999

Filed:

Jan 3, 1997

Appl. No.:

8/778810

Inventors:

Curtis Gray - Stratford CT
Michael J. McKenna - Shelton CT
Christine Weigand - Milford CT

Assignee:

BIC Corporation - Milford CT

International Classification:

B43K 700

US Classification:

401192

Abstract:

A writing instrument is disclosed which includes a cartridge having a writing tip portion and a unique barrel having a generally elongated tubular configuration and an outer surface portion having a plurality of spiral shaped surface irregularities in the form of surface grooves which enhance the gripping of the barrel by the user. The barrel also includes a multisided inner opening which, combined with the outer grooved surface, provides a unique array of light transmission and diffusion which distorts the appearance of the cartridge and the barrel thus causing the barrel to have a translucent character. A method of producing barrel stock from which the barrels may be cut is also disclosed.

US Patent:

20180267053, Sep 20, 2018

Filed:

Mar 12, 2018

Appl. No.:

15/918489

Inventors:

- Frisco TX, US
Michael P. McKenna - Branford CT, US

International Classification:

G01N 33/68
G06F 19/18
C12Q 1/6883
G01N 33/53

Abstract:

Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 or less of a legacy clinical sample.

US Patent:

20160139139, May 19, 2016

Filed:

Jan 27, 2016

Appl. No.:

15/007786

Inventors:

- Frisco TX, US
Michael P. McKenna - Branford CT, US

International Classification:

G01N 33/68
G06F 19/18

Abstract:

Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL. or less of a legacy clinical sample.